Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-1: olverembatinib plus chemotherapy versus investigator-chosen TKI plus chemotherapy in newly diagnosed Ph-positive acute lymphoblastic leukemia
CTR20232680Phase 3Active
- Sponsor
- 广州顺健生物医药科技有限公司
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by 广州顺健生物医药科技有限公司. Started Sep 2023; status: active.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20232680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232680.